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oligonucleotides has been shown to induce signiﬁcant levels
of dystrophin restoration in mdx, a mouse model of Duchenne
muscular dystrophy. This translates into signiﬁcant improve-
ment in key disease indicators in muscle, cardio-respiratory
function, heart, and the CNS. Here we examine the relationship
between muscle ﬁber type, based on myosin heavy chain
(MHC) proﬁle, and the ability of tc-DNA to restore not only
dystrophin but also other members of the dystrophin-associ-
ated glycoprotein complex (DAPC). We ﬁrst proﬁled this rela-
tionship in untreated mdx muscle, and we found that all ﬁber
types support reversion events to a dystrophin-positive state,
in an unbiased manner. Importantly, we show that only a small
fraction of revertant ﬁbers expressed other members of the
DAPC. Immunoblot analysis of protein levels, however, re-
vealed robust expression of these components, which failed to
correctly localize to the sarcolemma. We then show that
tc-DNA treatment leads to nearly all ﬁbers expressing not
only dystrophin but also other key components of the DAPC.
Of signiﬁcance, our work shows that MHC ﬁber type does
not bias the expression of any of these important proteins.
This work also highlights that the improved muscle physiology
following tc-DNA treatment reported previously results from
the complete restoration of the dystrophin complex in all
MHCII ﬁbers with equal efﬁciencies.Received 20 July 2017; accepted 21 October 2017;
https://doi.org/10.1016/j.omtn.2017.10.014.
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Duchenne muscular dystrophy (DMD) affects 1:5,000 male births,
and it is the most common fatal childhood muscular disease.1,2 Mu-
tations in the DMD gene affect expression of dystrophin, a protein
normally localized to the inner surface of the sarcolemma in muscle
ﬁbers.3,4 Dystrophin together with a number of other proteins that
constitute the dystrophin-associated glycoprotein complex (DAPC)
acts to link the muscle ﬁber cytoskeleton, the sarcolemma, and the
extracellular matrix (ECM) into a functional unit that maintains mus-
cle integrity.5,6 The DAPC is composed of three sub-complexes: (1)
the sarcoglycans (a, b, g, and d); (2) syntrophin, nNOS, and dystro-
brevin; and (3) a and b dystroglycan. The absence of dystrophin re-
sults in a drastic reduction of all components of the DAPC at theMolecular Ther
This is an open access article under tsarcolemma, and it renders muscle cells prone to stretch-induced
muscle damage.7
A number of drug-based or surgical procedures have been developed,
including the use of corticosteroids or addressing scoliosis, that
greatly improve the quality of life for DMD patients or delay disease
onset.8,9 However, none has completely halted progression of the dis-
ease. Gene-based approaches that aim to restore dystrophin in muscle
hold great promise. One attractive approach is to take advantage of
the molecular structure of the dystrophin gene and to use antisense
oligonucleotides (AONs) to promote exon skipping to bypass
mutated stretches of DNA and restore the open reading frame.10
The aim of the current study is to establish expression of a functional,
albeit internally deleted, dystrophin protein. Restoration of dystro-
phin expression by exon skipping has been proven to be efﬁcacious
in vitro, in animal models and in DMD patients.11–13 Several classes
of chemical modiﬁcations have been developed for AON-mediated
exon skipping, among which are 20O-methylribooligonucleoside-
phosphorothioate (20OMe), phosphorodiamidate morpholino oligo-
mers (PMOs), and tricyclo-DNA (tc-DNA). The latter has a number
of properties that make it an attractive chemistry to exploit for ther-
apeutic uses, including high RNA afﬁnity, resistance to nuclease activ-
ity, and the ability to form nanoparticles that may facilitate uptake
into cells.14–16 We have recently shown, using mdx mice as a rodent
model for DMD, that tc-DNA mediates unprecedented levels of exon
skipping after systemic delivery not only in skeletal muscle but also in
the heart and brain.16 This translated into normalization of speciﬁc
force in the tibialis anterior muscle as well as improved cardiovascular
function and the correction of behavioral characteristics.16
A number of studies using AONs in both mdx mice and DMD pa-
tients have shown restoration of dystrophin in a subset of muscle ﬁ-
bers.13,17,18 Most skeletal muscles are composed of a heterogeneousapy: Nucleic Acids Vol. 9 December 2017 ª 2017 The Authors. 409
he CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Myosin Heavy Chain Profile of the Tibialis
Anterior Muscle
(A) Immunohistochemical images of TA muscle from 20-
to 22-week-old male wild-type,mdx, and tc-DNA-treated
mdx mice. Green fibers signify the expression of MHCIIA
with MHCIIB appearing as red. Non-green and red fibers
represent MHCIIX. (B) MHC profile in the three cohorts.
Results show that WT, mdx, and tc-DNA-treated mdx
mice have the same proportion of each MHC subtype
(n = 4 for each cohort). Statistical analysis was performed
by one-way ANOVA followed by Bonferroni correction for
multiple comparison.
Molecular Therapy: Nucleic Acidspopulation of muscle ﬁbers that differ in their metabolic properties as
well as contractile speeds, a feature impacted by the type of myosin
heavy chain (MHC) being expressed. Muscle of adult mice is
composed of MHCI, MHCIIA, MHCIIX, and MHCIIB ﬁbers.
MHCI has the slowest contraction rate and is highly reliant on oxida-
tive phosphorylation for energy production. MHCIIB is at the other
end of the spectrum, displaying the fastest contraction rates and high-
ly dependent on glycolytic metabolism. Slow ﬁbers are invested with a
higher capillary density as well as thicker ECM compared to fast ﬁ-
bers.19,20 Fast-contracting ﬁber with its decreased ability to store en-
ergy in the ECM is hypothesized to facilitate a greater proportion of
force transfer to the skeletal elements.21 A number of studies have
shown that slow muscle, based on MHC expression proﬁling as
well as physical measures, expresses more dystrophin than fast mus-
cle22 and that fast muscle ﬁbers are preferentially affected in DMD.23
Here we examined whether the efﬁcacy of dystrophin exon skipping
is inﬂuenced by MHC ﬁber type, possibly due to ﬁber type differ-
ences in ECM thickness impacting on the rate of AON diffusion
into the muscle ﬁber. We ﬁrst proﬁled revertant ﬁbers in mdx
mice with a view of establishing whether their appearance was
related to MHC ﬁber type. We then investigated the relationship be-
tween the restoration of dystrophin and of members of the three
DAPC sub-complexes by treatment with tc-DNA and by MHC ﬁber
type. Our results demonstrate that revertant ﬁbers caused by
splicing events in untreated mdx mice develop in a manner inde-
pendent of MHC ﬁber type. Importantly, we show that only a frac-
tion of revertant ﬁbers also express DAPC members. Treatment
with tc-DNA results in over 90% of all ﬁbers expressing all proteins
examined, with no observed bias toward any one MHC ﬁber type.
These data demonstrate that tc-DNA treatment is able to induce
exon skipping in all MHCII ﬁbers.410 Molecular Therapy: Nucleic Acids Vol. 9 December 2017RESULTS
We ﬁrst established the MHC landscape of the
tibialis anterior (TA) muscle and the effect
wrought upon it ﬁrst by the mdx mutation
and second after treatment with AONs con-
sisting of tc-DNA. Previous work has reported
that the mdx mutation affects the MHC ﬁber
proﬁle in a muscle-speciﬁc manner, with the
extensor digitorum longus (EDL) and soleusunchanged by the mutation24 whereas the diaphragm contains
slower isoforms compared to control.25 Analysis of the TA muscle
of wild-type (WT) mice at its maximum circumference revealed
an approximate ratio of 1:3:6 with respect to MHCIIA, MHCIIX,
and MHCIIB ﬁbers (Figures 1A and 1B). The same ratios were
found in the TA muscles of mdx mice and tc-DNA-treated mdx
mice (Figures 1A and 1B). Statistical analysis failed to reveal signif-
icant differences in the proportions of a particular MHC isoform
among the three cohorts. Therefore, the MHCII proﬁle of TA mus-
cle was not affected by the absence of dystrophin or by treatment
with tc-DNA.
We next examined the relationship between revertant ﬁbers
(dystrophin+), co-expression of one member of each of the three
DAPC sub-complexes, and MHCII class in untreated mdx mice.
There were approximately 60 dystrophin+ ﬁbers in the TA muscle
of 20- to 22-week-old mice. The ratio of dystrophin+ in relation
to MHC ﬁber type (IIA:IIX:IIB) was approximately 1:3:6, respec-
tively. Therefore, the segregation of dystrophin+ ﬁbers within
MHC subtypes followed the distribution of each isoform. Hence,
there was no bias toward any one MHC isoform with regard to
reversion to a dystrophin-positive state (Figure 2A). Proﬁling the
expression of b-sarcoglycan, nNOS, and a-dystroglycan revealed a
number of interesting features. First, they were found in all three
MHC ﬁber isoforms, and, similar to dystrophin, there was no bias
toward any one MHCII type (Figure 2A). b-sarcoglycan-, nNOS-,
and a-dystroglycan-expressing ﬁbers were a subset of those that ex-
pressed dystrophin. However, the number of ﬁbers that expressed
these three molecules was always lower than the number expressing
dystrophin (Figure 2B). Indeed, nNOS-positive ﬁbers, although be-
ing the most frequent of the three, only represented about half of
dystrophin-positive ﬁbers.
Figure 2. Expression of Dystrophin, b-Sacroglycan, nNOS, and a-Dystroglycan in the TA Muscle of 20- to 22-Week-Old Male mdx Mice
(A) Each row shows the entire TAmuscle stained for one of the four molecules together with amagnified detailed image. All positive fibers were correlated to the expression of
an MHC isoform, and their distribution is given as the total number as well as proportion to the frequency of the MHC isoform. (B) Graph showing the proportion of TA fibers
expressing the four investigated molecules (n = 4 for each cohort). *p < 0.05, **p < 0.01, and ***p < 0.001. Statistical analysis was performed by one-way ANOVA followed by
Bonferroni correction for multiple comparison.
www.moleculartherapy.orgThese results show that revertant ﬁbers do not express the full com-
plement of DAPC components.
Thereafter, we examined the expression of dystrophin, b-sarcogly-
can, nNOS, and a-dystroglycan in relation to MHC ﬁber type inthe TA muscle of tc-DNA-treated mdx mice. Immunostaining re-
vealed that the majority of ﬁbers were positive for dystrophin after
tc-DNA treatment, which is in agreement with previous ﬁndings
of Goyenvalle and colleagues16 (Figure 3A). Robust expression of
dystrophin was found in all MHC ﬁber types, and analysis ofMolecular Therapy: Nucleic Acids Vol. 9 December 2017 411
Figure 3. Expression of Dystrophin, b-Sarcoglycan, nNOS, and a-Dystroglycan in the TA Muscle of 20- to 22-Week-Old Male tc-DNA-Treated mdx Mice
(A) Each row shows the entire TA muscle immunostained for dystrophin, b-sarcoglycan, nNOS, and a-dystroglycan together with a magnified detailed image. All positive
fibers were correlated to the expression of an MHC isoform, and their distribution is given as the total number as well as proportion to the frequency of the MHC isoform.
(B) Graph showing the proportion of TA fibers from tc-DNA-treated mdx mice expressing the four investigated molecules (n = 4 for each cohort). *p < 0.05, **p < 0.01, and
***p < 0.001. Statistical analysis was performed by one-way ANOVA followed by Bonferroni correction for multiple comparison.
Molecular Therapy: Nucleic Acidsfrequency with respect to ﬁber proportion revealed that there was
no bias to any one ﬁber type. Immunostaining for b-sacroglycan,
nNOS, and a-dystroglycan revealed the same features as dystro-
phin; the vast majority of ﬁbers expressed the three proteins, and
their presence in a particular MHC ﬁber type was proportional412 Molecular Therapy: Nucleic Acids Vol. 9 December 2017to the frequency of that form (Figure 3A). We then compared
the relative frequency of ﬁbers expressing each of the four proteins.
We found there were signiﬁcantly more ﬁbers that expressed dys-
trophin than the other three components of the DAPC assessed
(Figure 3B).
Figure 4. Semiquantitative Analysis of DAPC Restoration following tc-DNA Treatment of 20- to 22-Week-Old Male mdx Mice
Untreated and tc-DNA-treatedmuscle shows high levels of individual proteins inMHCIIA fibers (white arrows) compared toMHCIIB fibers (yellow arrows). Intensities from over
30 regions for each fiber type were taken from revertant untreatedmdx and set to a reference value of one. Similar numbers of intensity readings were plotted for each fiber
(legend continued on next page)
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Figure 5. Western Blot Analysis of DAPC Proteins in
20- to 22-Week-Old Male Mice
(A) Western blot image of DAPC proteins in the TA
muscle. (B) Quantification of DAPC proteins relative to
GAPDH. Note the robust expression of b-sarcoglycan,
nNOS, and a-dystroglycan in untreated mdx muscle
(n = 3 for each cohort). **p < 0.01. Statistical analysis was
performed using two-tailed t test.
Molecular Therapy: Nucleic AcidsThese results show that tc-DNA treatment ofmdxmice results in the
restoration of dystrophin in the majority of muscle ﬁbers. This is also
the case for a-dystroglycan, b-sarcoglycan, and nNOS. However, the
number of ﬁbers expressing b-sarcoglycan, nNOS, and a-dystrogly-
can was signiﬁcantly lower compared to dystrophin.
Previous work has shown that contractile properties of a muscle ﬁber
impact both qualitatively and quantitatively on its surrounding
ECM.19,20 Here we examined the relationship between MHC ﬁber
type and expression of components of the DAPC as well as an ECM
component, collagen IV, using semiquantitative techniques. Fluores-
cence intensity was used as previously described to gain an indication
of the amount of protein at the sarcolemma.18We ﬁrst determined the
signal intensity for the ﬁve proteins in question in relation to MHC ﬁ-
ber type in the revertant ﬁbers from the mdx mouse. For each ﬁber
type, the signal intensity was set to a reference value of 1. Thereafter
the same procedure was repeated for the tc-DNA-treated muscle,
and intensity was compared to that of the untreated TA muscle. The
outcome of the process showed that tc-DNA treatment resulted in
an increase in the amount of each protein of interest in all ﬁber types
compared to untreated revertant mdx ﬁbers (Figure 4). We also
measured the thickness of the expression domain for each of the ﬁve
marker proteins, revealing that each expression domain was thicker
in MHCIIA ﬁbers compared to MHCIIB ﬁbers (Figure 4). This rela-
tionship persisted following tc-DNA treatment. Second, we found
that there was an increase in the expression domain following tc-DNA
treatment for all ﬁber types (Figure 4).
These results show that the amount of each component of the DAPC
and collagen IV at the sarcolemmawere elevated above those found in
revertant ﬁbers.
Last, we examined the effect of tc-DNA treatment on the total level of
expression of the DAPC components under investigation here. Totype from tc-DNA-treated mdxmuscle. In all cases there was a significant increase in intensity compared to untre
expression domain was measured and plotted for each MHC isoform originating from revertant untreated mdx an
expression domains compared toMHCIIB. Thickness for expression domains irrespective of MHC fiber type was in
bar applicable to all images represents 50 mm. *p < 0.05, **p < 0.01, and ***p < 0.001. Statistical analysis was p
414 Molecular Therapy: Nucleic Acids Vol. 9 December 2017that end we carried out quantitation of western
blots. Our results showed that there was a
14-fold increase in the amount of dystrophin
following tc-DNA treatment (Figures 5A and
5B). Interestingly, we found robust expressionof b-sarcoglycan, nNOS, and a-dystroglycan in untreated mdx mus-
cle and that their levels were not changed signiﬁcantly by tc-DNA
treatment. In summary, components of the DAPC are translated in
the absence of dystrophin, but they fail to localize to the sarcolemma.
DISCUSSION
Tc-DNA chemistry is an exciting development in the area of molec-
ular medicine. We have previously shown that, in the context of a
mouse model of DMD, tc-DNA treatment was more efﬁcacious in
restoring muscle function than many other approaches.16 Of partic-
ular note was the ﬁnding that tc-DNA AONs spontaneously form
nanoparticles, which are believed to promote entry into the cell and
may be the reason why these were able to penetrate the heart and
the brain.16 In this study, we investigated the relationship between
muscle compositions in terms of MHC ﬁber type and dystrophin
restoration by tc-DNA AON with a view to developing an under-
standing of its speciﬁcity of action.
We commenced the study by comparing the MHC proﬁle of the TA
muscle in the three cohorts under investigation: WT, mdx, and
tc-DNA-treated mdx mice. We found that all three shared the same
MHC proﬁle. Previous studies have shown that the MHC proﬁle of
the diaphragm underwent a signiﬁcant change in its MHC composi-
tions, with a decrease in the proportion of MHCIIB+ ﬁbers and a
concomitant increase in the number of MHCI+ ﬁbers.25 The change
in MHC proﬁle was proposed to be an adaptive step to preserve con-
tractile function and ﬁber integrity by lowering energy requirements.
In contrast, the EDL and soleus muscles of themdx were shown to be
identical to those from WT in terms of MHC proﬁle.24 Our results
here now add the TA muscle to the list of muscles that show normal
MHC proﬁle in the mdx mouse. Nevertheless, all mdx muscles have
reduced speciﬁc force. We propose that, if a change toward a slower
MHC proﬁle is an adaptive change to the absence of dystrophin, it
must be a secondary step that is dependent on other upstream factors,ated revertant fibers of the same MHC type. Thickness of
d tc-DNA-treated mdx muscle. MHCIIA fibers had thicker
creased by tc-DNA treatment (n = 4 for each cohort). Scale
erformed using two-tailed t test.
www.moleculartherapy.orgone of which could be contractile activity, which would explain the
change in constantly used muscles like the diaphragm and not in
limb muscles. A number of studies have proposed mechanisms to
explain the reduced speciﬁc force in mdx, including nitrosylation of
the contractile machinery, which, if it occurred, would lead to long-
term damage due to low turnover rate of MHC.26,27 However, recent
work has shown that theMHC frommdx functions normally in terms
of cross-bridging, which argues against long-term effect of altered
muscle function.28 This suggestion is indirectly corroborated by the
efﬁcacy of tc-DNA treatment being able to normalize speciﬁc force
in the TA muscle of mdx mice.16
Our work examining the distribution of the DAPC protein in un-
treated mdx muscle offers interesting insights into the formation of
the functional unit. First, we show that there was no bias in terms
to MHC ﬁber type and the appearance of dystrophin. Therefore, if
metabolic activity were to generate differential cellular stress based
on ﬁber contraction rate, then this metric does not impact on the
splicing events that restore dystrophin expression in mdx muscle.
Furthermore, when serendipitous events lead to the restoration of
dystrophin, they bring back the protein in a relatively normal manner
with respect to MHC ﬁber type, with higher expression in slow ﬁbers
compared to faster ones.22 Additionally, there was no bias in terms of
MHC ﬁber type and any of the other components of the DAPC exam-
ined here.
An interesting feature highlighted by our work in this section was the
ﬁnding that revertant ﬁbers (dystrophin+) are heterogeneous in terms
of their DAPC composition as follows: dystrophin+ > nNOS+ >
a-dystroglycan (aDG)+ > b-sarcoglycan (ßSG)+. Our quantiﬁcations
of DAPC expression in revertant ﬁbers extends previous ﬁndings of
Lu et al.29 who showed co-expression of DAPC proteins in clusters
of revertant ﬁbers. Interestingly, our western blotting data agree
with prior reports showing an abundance of nNOS, aDG, and ßSG
total protein inmdxmuscle.30 It follows, therefore, that a mechanism
must be active that prevents the translocation of DAPC proteins to
the sarcolemma of some revertant ﬁbers. One possibility is that
they may not have had sufﬁcient time to correctly translocate. This
is, however, unlikely since revertant ﬁbers form from events that
occur in muscle precursors.31 Another possibility is linked to the
poor diffusion of dystrophin within the myoﬁber sarcolemma,
limiting membrane expression to spatially conﬁned nuclear domains.
Moving out of this dystrophin domain during serial sectioning would
affect detection of other components of the DAPC. While this phe-
nomenon can contribute to a decreased co-detection of dystrophin
and DAPC proteins, it should be noted that dystrophin expression
in revertant ﬁbers has been reported to span membrane segments
of 654 ± 409 mm.32 It is unlikely that exiting a nuclear domain during
collection of serial sections over a length of muscle not exceeding
160 mm (16 serial sections) could on its own account for over half
of the revertant ﬁbers lacking expression of other DAPC proteins
(Figure 3B). It is therefore possible that a signiﬁcant proportion of
internally deleted dystrophins generated by revertant ﬁbers is not
able to assemble a functional DAPC but can be correctly localizedto the membrane. This hypothesis would be consistent with reports
of truncated or internally deleted dystrophins that lack the
cysteine-rich domain required for interaction with the DAPC but
can still be correctly localized to the sarcolemma.33 Overall our results
highlight two interesting ﬁndings: ﬁrst, the majority of revertant ﬁ-
bers produce internally deleted forms of dystrophin that cannot func-
tionally contribute to force transduction, since they are uncoupled
from the dystroglycan and sarcoglycan complexes; and, second,
mdx muscle has a rich pool of DAPC proteins available for recruit-
ment to the sarcolemma upon expression of a functional dystrophin
protein.
Restoration of dystrophin expression following tc-DNA treatment re-
sulted in near total coverage of TA ﬁbers, consistent with our previous
work.16 We do not believe that the variation in the afﬁnities of anti-
bodies for their epitopes is a decisive factor in showing a variation
in DAPC proﬁle betweenmdx and tc-mdxmice. We base this conclu-
sion on the fact that have we have compared the same strain (indeed
littermates) with or without tc-DNA treatment. Therefore, the
differing afﬁnities between antibodies for their particular epitope
would remain a constant factor. Hence, the appearance of a molecule
at the sarcolemma in tc-mdx mice compared to mdx must be due to
changes in the expression levels of the protein. The results of this
study demonstrate that there is no bias with regard to dystrophin
expression induction following tc-DNA treatment and ﬁber type.
This is, we believe, highly relevant and important for prospective
translation into therapies.
Previous work carried out in humans revealed restoration of dystro-
phin in a subset of muscle ﬁbers, a differential restoration that may
have been inﬂuenced by the structural properties of the muscle.13,17
Indeed, it is well established that slow muscle ﬁbers have a thicker
ECM in comparison to fast ﬁbers.19,20 It would, therefore, be reason-
able to postulate that slow ﬁbers are more resistant to inﬁltration by
tc-DNAAON.However, our work shows that, at least in terms of type
II ﬁber sub-types, there is no preference to exon skipping. This bodes
well for the use of this chemistry in a spectrum of muscles with
differing ﬁber composition, as it seems they are all in principle able
to take up the tc-DNA AON. In addition, we show that MHC ﬁber
type does not inﬂuence the restoration of the other components
examined here. Also, tc-DNA treatment leads to more of each
component at the sarcolemma compared to revertant mdx ﬁbers.
Nevertheless, it is worth noting that not all the ﬁbers that expressed
dystrophin contained the other three components of the DAPC
examine here (dystrophin+ > nNOS+ > ßSG+ > aDG+). This again
highlights the point that the presence of the DAPC proteins does
not necessarily translate into them being assembled into a functional
complex.
There is a dearth of knowledge regarding mechanisms that regulate
the formation of the DAPC, a gap in our understanding that requires
urgent attention. One potential consequence of this gap in our un-
derstanding is that it is possible that we will develop the means
of inducing protein dystrophin expression but that it may notMolecular Therapy: Nucleic Acids Vol. 9 December 2017 415
Molecular Therapy: Nucleic Acidstranslocate to the correct sub-cellular region and, therefore, reduce
therapeutic beneﬁt. Insights into this process could be gained by
examining revertant ﬁbers. Nevertheless, tc-DNA treatment resulted
in over 90% of the ﬁbers having all four of the DAPC components at
the sarcoplasm. We believe that this high level of DAPC restoration
explains the normalization of speciﬁc force following tc-DNA treat-
ment, and, again, it bodes well for translation into the clinic since
previous studies have demonstrated that restoration of dystrophin
protein levels to 10%–20% of WT results in improved health.34
In summary, we show that reversion of ﬁbers to a dystrophin-positive
state in mdx mice is a stochastic process with regard to MHC ﬁber
type. However, expression of dystrophin in mdx revertant ﬁbers
only translates into a minority (>25%) of ﬁbers expressing members
of the three sub-complexes. Tc-DNA treatment results in over 90% of
ﬁbers’ expression of dystrophin as well as members of the three sub-
complexes in the TA muscle. Importantly, there is no bias in terms of
expression of any component with regard to MHC ﬁber type. This
work shows that, in principle, tc-DNA treatment is equally efﬁcacious
across all type II ﬁbers.
MATERIALS AND METHODS
Animals
Animal procedures were performed in accordance with national and
European legislation, approved by the French government (Ministère
de l’enseignement supérieur et de la recherche, Autorisation APAFiS
6518). Mdx (C57BL/10ScSc-Dmdmdx/J) and C57BL/10 mice were
bred in our speciﬁc opportunistic pathogen-free (SOPF) animal facil-
ity at the Plateform 2Care, UFR des Sciences de la santé, Université de
Versailles Saint Quentin, and they were maintained in a standard
12-hour light/dark cycle with free access to deionized water and stan-
dard laboratory chow (M20, Dietex) ad libitum. Mice were weaned at
postnatal weeks 4–5 and 2–5 individuals were housed per cage. Mice
were randomly allocated to treatment and control groups, ensuring
equal numbers of control and treated mice within the same litters.
The tc-DNA-AON PS M23D (50-AACCTCGGCTTACCT-30) target-
ing the donor splice site of exon 23 of the mouse dystrophin pre-
mRNA used in this study was synthesized by SYNTHENA (Bern,
Switzerland). The 6- to 8-week-old male mdx mice were injected
intravenously in the retro-orbital sinus, under general anesthesia us-
ing 1.5%–2% isoﬂurane, once a week with 200 mg/kg/week of the
M23D-tc-DNA for a period of 12 weeks. Treated mice were sacriﬁced
2 weeks after the last injection, and muscles and tissues were har-
vested and snap-frozen in liquid nitrogen-cooled isopentane and
stored at 80C before further analysis.
Immunohistochemistry
Dissected and frozen muscles were mounted in Tissue Tech freezing
medium (Jung) cooled by dry ice/ethanol. Immunohistochemistry
staining was performed on 10-mm cryosections that were dried for
30 min at room temperature (RT) prior to three washes in 1 PBS.
Muscle sections were incubated in permeabilization buffer solution
(0.952 g HEPES, 0.260 g MgCl2, 0.584 g NaCl, 0.1 g Sodium azide,416 Molecular Therapy: Nucleic Acids Vol. 9 December 201720.54 g Sucrose, and 1 mL Triton X-100) for 15 min at room temper-
ature, before the application of block wash buffer (PBS with 5% fetal
calf serum [v/v] and 0.05% Triton X-100) for 30 min at room
temperature.
Primary antibodies were pre-blocked in wash buffer for 30 min prior
to incubation onto muscle sections overnight at 4C. Pre-blocked-in
wash buffer was performed for all secondary antibodies (in dark) for a
minimum of 30 min prior to their addition onto the slides. Sections
were then incubated for 1 hr in the dark at room temperature. Finally,
slides were mounted in ﬂuorescent mounting medium, and myonu-
clei were visualized using 2.5mg/mLDAPI. Details of primary and sec-
ondary antibodies are given in Supplemental Materials and Methods.
Western Blotting
TA proteins from 20- to 22-week-old male mice (20 mg/lane) were
separated on 4%–12% gradient SDS-PAGE gels (Invitrogen), trans-
ferred to nitrocellulose membranes (Whatman), and blocked with
5% skim milk in 0.1% Tween 20/Tris-buffered saline. Membranes
were cut at appropriate molecular weights in order to allow for
simultaneous probing of the exact same samples for dystrophin and
multiple DAPC proteins. Membrane strips were then incubated
with appropriate primary antibodies overnight at 4C, followed by
a 1-hr incubation at room temperature with the appropriate horse-
radish peroxidase-conjugated secondary antibodies (Jackson Im-
munoResearch Laboratories). Protein bands were visualized using
enhanced chemiluminescence reagents (Pierce). Signal was detected
on X-ray ﬁlm (RPI) at multiple exposures. For densitometric analysis,
protein band intensities from multiple non-saturated ﬁlm exposures
were quantiﬁed using ImageJ (NIH). Values in the linear range of
pixel intensities were selected for quantiﬁcations. Signal intensities
were normalized to GAPDH, used as an internal loading control,
and probed on the samemembrane. Details of primary and secondary
antibodies are given in Supplemental Materials and Methods.
Semiquantitative Measures of Sarcolemma Protein Expression
Intensity of signals of protein of interest was measured as previously
described.18 Brieﬂy, membrane signal intensities of approximately
30 muscle ﬁbers of each MHC phenotype (IIA, IIX, and IIB) in
each TA muscle section from mdx mice and mdx mice treated with
tc-DNA were measured. Fiji software was used to measure signal
from area of interest after images had been corrected for background
to avoid regions of signal saturation. To calculate relative signal inten-
sity levels, individual measurements from treated and control ﬁbers
were taken as a percentage of mean of control samples.
Sarcolemma Thickness Measurement
Connective tissue thickness between approximately 30 ﬁbers of the
same MHC phenotypes (IIA-IIA, IIX-IIX, and IIB-IIB) of TA muscle
sections was measured using Fiji software. One measurement on the
constant connective tissue thickness and multiple measurements on
the ﬂuctuating connective tissue thickness areas between each two
myoﬁbers that expressed the same MHC isoform were taken on all
muscle sections of mdx mice and mdx mice treated with tc-DNA.
www.moleculartherapy.orgImaging and Analysis
A ﬂuorescence microscope (Zeiss AxioImegar A1) was used to
examine immunoﬂuorescently stained sections, and images were
captured using an Axiocam digital camera with Zeiss Axiovision
computer software version 4.8.
Statistical Analysis
Data are presented as mean ± SE. Signiﬁcant differences between two
groups were performed by two-tailed Student’s t test for independent
variables. Differences among groups were analyzed by one-way
ANOVA followed by Bonferroni multiple comparison tests as
appropriate. Statistical analysis was performed on GraphPad Prism
software. Differences were considered statistically signiﬁcant at
*p < 0.05, **p < 0.01, or ***p < 0.001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Materials and
Methods and can be found with this article online at https://doi.
org/10.1016/j.omtn.2017.10.014.
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